Kozak & Associates’s MetLife MET Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$940 Sell
11
-2
-15% -$161 ﹤0.01% 386
2026
Q1
$957 Hold
13
﹤0.01% 397
2025
Q4
$1K Hold
13
﹤0.01% 390
2025
Q3
$944 Hold
13
﹤0.01% 408
2025
Q2
$1.02K Sell
13
-85
-87% -$6.56K ﹤0.01% 370
2025
Q1
$7.17K Sell
98
-215
-69% -$17.9K ﹤0.01% 247
2024
Q4
$25.7K Sell
313
-74
-19% -$6.16K 0.01% 167
2024
Q3
$33K Buy
387
+3
+0.8% +$224 0.01% 155
2024
Q2
$26.9K Buy
384
+3
+0.8% +$214 0.01% 157
2024
Q1
$28K Buy
381
+13
+4% +$906 0.01% 160
2023
Q4
$25.1K Sell
368
-535
-59% -$33.5K 0.01% 174
2023
Q3
$55.4K Sell
903
-210
-19% -$13.1K 0.02% 130
2023
Q2
$63.8K Hold
1,113
0.03% 125
2023
Q1
$64.5K Sell
1,113
-137
-11% -$9.25K 0.03% 130
2022
Q4
$90K Hold
1,250
0.04% 117
2022
Q3
$79K Hold
1,250
0.05% 117
2022
Q2
$79K Buy
1,250
+8
+0.6% +$530 0.05% 122
2022
Q1
$80K Hold
1,242
0.05% 127
2021
Q4
$80K Buy
1,242
+145
+13% +$9.1K 0.05% 127
2021
Q3
$70K Buy
+1,097
New +$66K 0.04% 132

Other funds holding MET

Kozak & Associates's MET Position: Q2 2026 in Review

Kozak & Associates reduced its MetLife (MET) stake by 15% in Q2 2026, selling an estimated $161 and leaving 11 shares worth $940. The position accounts for ﹤0.01% of the portfolio, ranked #386.

Kozak & Associates first reported a position in MET in Q3 2021 and has held it in 20 quarters since. The position peaked at $90K in Q4 2022. 1,445 funds tracked by Wall St. Rank hold MET as of Q2 2026.

  • Kozak & Associates held 11 shares of MetLife worth $940 as of Q2 2026.
  • Kozak & Associates sold 2 MetLife shares in Q2 2026, an estimated $161.
  • MetLife made up ﹤0.01% of Kozak & Associates's portfolio in Q2 2026, its #386 holding.
  • Kozak & Associates first reported a position in MetLife in Q3 2021 and has held it in 20 quarters since.
  • Kozak & Associates's MetLife position peaked at $90K in Q4 2022.
  • 1,445 funds tracked by Wall St. Rank held MetLife as of Q2 2026.

Based on Kozak & Associates's 13F filing for Q2 2026, filed 2 Jul 2026.